Human Genome Epidemiology Literature Finder
Records 1 - 5 (of 5 Records) |
Query Trace: Colorectal Neoplasms and meta-analysis and NRAS[original query] |
---|
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 Jan 26 (1): 13-21. Sorich M J, Wiese M D, Rowland A, Kichenadasse G, McKinnon R A, Karapetis C |
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta oncologica (Stockholm, Sweden) 2014 Jul 53 (7): 852-64. Therkildsen Christina, Bergmann Troels K, Henrichsen-Schnack Tine, Ladelund Steen, Nilbert M |
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World journal of gastroenterology 2016 Aug 22 (30): 6944-54. Lo Nigro Cristiana, Ricci Vincenzo, Vivenza Daniela, Granetto Cristina, Fabozzi Teresa, Miraglio Emanuela, Merlano Marco |
Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis. Molecular and clinical oncology 2016 Jun 4 (6): 1017-1024. Lin L I, Chen Lu-Lu, Wang You, Meng Xiang-Yu, Liang Chen, Zhou Fu-Xia |
A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer. Gastroenterology research 2020 11 13 (5): 184-198. Levin-Sparenberg Elizabeth, Bylsma Lauren C, Lowe Kimberly, Sangare Laura, Fryzek Jon P, Alexander Dominik |
- Page last reviewed:Feb 1, 2023
- Page last updated:May 22, 2023
- Content source: